Gemalto Brings Strong Authentication to Healthcare Industry, Joins SAFE-BioPharma Association
AUSTIN, Texas, April 6, 2009 – Gemalto, the world leader in digital security, announced today that it has become a vendor partner of SAFE-BioPharma Association (http://www.safe-biopharma.org). Gemalto is joining with biopharmaceutical and healthcare industry leaders to help the industry achieve its common goal of a fully electronic business environment by 2012. Gemalto will contribute its expertise in smart card-based solutions for authentication, network security and digital signature.
Gemalto is the first smart card provider to join SAFE-BioPharma. Gemalto has been an active industry partner since 2004, when it began working with Pfizer to implement smart card employee badges that converge physical and logical access control onto a single identity credential. Gemalto is also a leading supplier of smart card based solutions for healthcare identity management worldwide.
The SAFE-BioPharma Association, based in Fort Lee, New Jersey, is a non-profit association that created and manages the SAFE-BioPharma™ digital identity and signature standard for the pharmaceutical and healthcare industries. The standard provides users with a secure, enforceable, and regulatory compliant way to verify identities of parties involved in electronic transactions and to apply their digital signatures to electronic documents.
“We welcome Gemalto to the growing SAFE-BioPharma vendor partner community. The company’s broad experience in smart cards, digital security, digital signature and identity management for healthcare, makes it a valuable global resource for life science companies,” said Mollie Shields-Uehling, president and chief executive officer, SAFE-BioPharma Association.
“Gemalto is a natural partner to companies using the SAFE-BioPharma standard, because we provide smart cards and tokens that serve as the secure carriers for digital identities. Two factor authentication (something you have and something you know) is an important building block for the success of many of the proposed Health IT initiatives underway in the US. For citizens to benefit from the new technologies, they need to be assured their privacy is protected,” said François Lasnier, vice president and general manager, Security, for Gemalto North America.
More information about Gemalto’s enterprise network security, authentication and digital signature solutions is available online.
Gemalto (Euronext NL 0000400653 GTO) is the world leader in digital security with 2008 annual revenues of €1.68 billion, and 10,000 employees operating out of 75 offices, research and service centers in 40 countries.
Gemalto is at the heart of our evolving digital society. The freedom to communicate, travel, shop, bank, entertain, and work – anytime, anywhere – has become an integral part of what people want and expect, in ways that are convenient, enjoyable and secure.
Gemalto delivers on the growing demands of billions of people worldwide for mobile connectivity, identity and data protection, credit card safety, health and transportation services, e-government and national security. We do this by supplying to governments, wireless operators, banks and enterprises a wide range of secure personal devices, such as subscriber identification modules (SIM) in mobile phones, smart banking cards, smart card access badges, electronic passports, and USB tokens for online identity protection. To complete the solution we also provide software, systems and services to help our customers achieve their goals.
As the use of Gemalto’s software and secure devices increases with the number of people interacting in the digital and wireless world, the company is poised to thrive over the coming years.
For more information please visit http://www.gemalto.com.
About SAFE-BioPharma Association (http://www.safe-biopharma.org)
SAFE-BioPharma Association is the non-profit association that created and manages the SAFE-BioPharma™ digital identity and signature standard for the pharmaceutical and healthcare industries.
The SAFE-BioPharma industry standard is used to mitigate legal, regulatory and other business risk associated with business-to-business and business-to-regulator electronic transactions. It facilitates interoperability by providing a secure, enforceable, and regulatory-compliant way to verify identities of parties involved in electronic transactions. SAFE-BioPharma’s vision is to be a catalyst in transforming the biopharmaceutical and healthcare communities to a fully electronic business environment by 2012.
The Association’s members include:
- Abbott (NYSE: ABT)
- Amgen (NASDAQ: AMGN)
- AstraZeneca (NYSE: AZN)
- Bristol-Myers Squibb (NYSE:BMY)
- GlaxoSmithKline (NYSE: GSK)
- Johnson & Johnson (NYSE: JNJ)
- Eli Lilly (NYSE: LLY)
- Merck (NYSE:MRK)
- National Notary Association
- Organon (NYSE: SGP)
- Pfizer (NYSE: PFE)
- Premier Inc.
- Procter & Gamble (NYSE: PG)
- Sanofi-Aventis (NYSE:SNY).
SAFE-BioPharma™ is a trademark of SAFE-BioPharma Association. Any use of this trademark requires approval from SAFE-BioPharma Association.